PDA - 医索

找到约 39 条结果

Phase lalb trial of zongertinib (Bl 1810631),aHER2-specific tyrosine kinase inhibitor in patients withHER2 aberration-positive solid tumors updatedPhase la data from Beamion LUNG-1, includingprogression-

医客学院 - 会议报告集

Neoadjuvant nivolumab plus chemotherapy vschemotherapy in patients with resectable NSCLC4-year update from CheckMate 816

医客学院 - 会议报告集

EFFICACY AND SAFETY OF SIGVOTATUGVEDOTIN, AN INVESTIGATIONAL ADC, IN NSCLCUPDATED PHASE 1 RESULTS(SGNB6A-001)

医客学院 - 会议报告集

Updated results from the Phase 1b2 HERKULES-3 studyERAS-007 plus encorafenib and cetuximab (Ec)inpatients (pts)with EC-naive metastatic BRAF V600Ecolorectal cancer (CRC)

医客学院 - 会议报告集

FUFA maintenance therapy with or withoutpanitumumab(pmab)in RAS wild-type metastaticcolorectal cancer(mCRC)(PanaMa, AlO KRK 0212)Updated efficacy analyses

医客学院 - 会议报告集

posters-Health-related quality of life in previously untreated patients with aRCC_CheckMate 9ER updated results

医客学院 - 会议报告集

WGI All Accepted Abstract Titles 2022_updated_new

医客学院 - 会议报告集

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer 5-Year Update of the Phase III KEYNOTE-407 Study

医客学院 - 药物研究

每日毅讯| JACC子刊：PCI术后双抗1月方案在糖尿病患者中的临床评估

每日毅讯既往的几个东亚研究（主要是韩国和日本）相继证实：PCI术后短期双抗治疗1-3月改为单抗治疗，可显著减少患者出血风险，且不会增加患者缺血事件的发生。近期，JACC Cardiovas Int杂志发表了STOPDAPT-2研究的糖尿病亚组结.....

学术资讯 - 临床医学

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus

医客学院

首页
上一页
1
2
3
4
下一页
尾页

今日实时热搜